1-4 of 4
Maneesh Tandon, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Cameron Wilson, Maneesh Tandon, MD, Travers Ching, Anna-Maria Fink, MD, Matthias Ritgen, MD, Eugen Tausch, MD, Karl-Anton Kreuzer, MD, William Schary, PhD, Clemens-Martin Wendtner, Barbara Eichhorst, MD, Stephan Stilgenbauer, MD, Yanwen Jiang, Michael Hallek, Kirsten Fischer, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-136977
Published: 2020
Journal Articles

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Kirsten Fischer, MD, Matthias Ritgen, Othman Al-Sawaf, MD, Sandra Robrecht, PhD, Maneesh Tandon, MD, Anna-Maria Fink, MD, Anke Schilhabel, PhD, Thomas Stübig, MD, Monika Brüggemann, MD, Yanwen Jiang, PhD, William Schary, PhD, Barbara F. Eichhorst, MD, Clemens-Martin Wendtner, MD, Eugen Tausch, Karl-Anton Kreuzer, MD PhD, Anton W Langerak, PhD, Valentin Goede, MD, Sebastian Böttcher, MD, Stephan Stilgenbauer, MD, Michael Kneba, PhD, Michael Hallek
Journal: Blood
Blood (2019) 134 (Supplement_1): 36.
https://doi.org/10.1182/blood-2019-125825
Published: 2019
Journal Articles

Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial

Othman Al-Sawaf, MD, Brittany Gentile, PhD, Jacob Devine, MA, Kavita Sail, PhD, Maneesh Tandon, MD, Anna-Maria Fink, MD, Nadine Kutsch, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4305.
https://doi.org/10.1182/blood-2019-126542
Published: 2019
Journal Articles

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Sandra Robrecht, PhD, Arijit Sinha, PhD, Maneesh Tandon, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4315.
https://doi.org/10.1182/blood-2019-126570
Published: 2019